Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
Clara Health

Investigation of the B- and T-cell Repertoire and Immune Response in COVID-19 Infection

Sponsored by the National Cancer Institute (NCI)


People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to a person s B and T cells. B and T cells are the major components of a person s immune response.

Objective: To examine how immune cells respond to COVID-19 infection.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study type: Observational Estimated Enrollment: 150 participants Estimated Study Start Date: April 27, 2020 Estimated Study Completion Date: December 1, 2024

Who is this study for?

Eligibility: Adults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past, as well as people who have not had COVID-19.

What should I expect?

  • Participants will be screened with medical record review.
  • Participants will give blood samples at NIH or at their local doctor's office or lab.
  • Participants who have or are suspected to have COVID-19 will give blood samples up to once a week during the active infection. This may include while they are in the hospital. They will also give a sample after the infection is over.
  • Participants who have recovered from a past COVID-19 infection will give a blood sample at least once, and maybe up to once per week for a few weeks.
  • Participants who do not have a history of COVID-19 infection will give a blood sample once. If they become infected in the future, they may be asked to give blood samples during infection and after, as listed above.
  • Participants who get a vaccine for COVID-19 in the future may be asked to give an extra blood sample.
  • Participants will be contacted by phone or email every 2 months for up to 2 years.

Connect with the study team

Thank you for your interest in advancing COVID-19 treatments.

Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.

If you have any difficulties or questions, please contact our support specialists at [email protected]

Have a question?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you’ll be connected to the study team.